High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma

European Journal of Surgical Oncology

Volumn 39, Issue 1, 2013, Pages 100-106

  Wu, X R ^a   Sha, J J ^a   Liu, D M ^a   Chen, Y H ^a   Yang, G L ^a   Zhang, J ^a   Chen, Y Y ^b   Bo, J J ^a   Huang, Y R ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clear cell renal carcinoma; Pirh2; Prognosis

Indexed keywords

P53 INDUCED RING H2 PROTEIN; RING FINGER PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 84870886194     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2012.10.004     Document Type: Article

References (23)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66.
2. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300.
3. N.K. Janzen, H.L. Kim, and R.A. Figlin Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852.
4. C. Eichelberg, K. Junker, and B. Ljungberg Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability Eur Urol 55 2009 851 863.
5. A.S. Belldegrun Renal cell carcinoma: prognostic factors and patient selection Eur Urol Suppl 6 2007 477 483.
6. Avram Hershko, and Aaron Ciechanover The ubiquitin system Annu Rev Biochem 67 1998 425 479.
7. V. Spataro, C. Norbury, and A.L. Harris The ubiquitin-proteasome pathway in cancer Br J Cancer 77 1998 448 455.
8. A.M. Burger, and A.K. Seth The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications Eur J Cancer 40 2004 2217 2229.
9. R.P. Leng, Y. Lin, and W. Ma Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation Cell 112 2003 779 791.
10. Z. Wang, B. Yang, and L. Dong A novel oncoprotein Pirh2: rising from the shadow of MDM2 Cancer Sci 102 2011 909 917.
11. W. Duan, L. Gao, and L.J. Druhan Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer J Natl Cancer Inst 96 2004 1718 1721.
12. Y. Su, P. Bai, and L.P. Zhu Expression and significance of Pirh2 and p27Kip1 in lung cancer Chin J Histochem Cytochem 16 2007 336 339.
13. I.R. Logan, L. Gaughan, and S.R. McCracken Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer Mol Cell Biol 26 2006 6502 6510.
14. C. Zhang, L. Tang, H. Ouyang, L. Ren, Y. Wu, and G. Luo The significance of Pirh2 mRNA expression in primary breast cancer Chin J Gen Surg 17 2008 444 448.
15. X.M. Wang, L.Y. Yang, L. Guo, C. Fan, and F. Wu p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection Cancer 115 2009 4554 4563.
16. X. Huang, X. Qian, and C. Cheng Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation Hum Pathol 42 2011 507 515.
17. M. Shimada, K. Kitagawa, and Y. Dobashi High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers Cancer Sci 100 2009 866 872.
18. AJCC cancer staging manual 6th ed. 2002 Springer-Verlag New York.
19. S.A. Fuhrman, L.C. Lasky, and C. Limas Prognostic significance of morphologic parameters in renal cell carcinom Am J Surg Pathol 6 1982 655 663.
20. S. Maruyama, N. Miyajima, and M. Bohgaki Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA Mol Cell Biochem 307 2008 73 82.
21. S. Duan, Z. Yao, and D. Hou Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53 EMBO J 26 2007 3062 3074.
22. L. Wang, G. He, and P. Zhang Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53 Mol Biol Rep 38 2011 229 236.
23. T. Hattori, T. Isobe, and K. Abe Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1 Cancer Res 67 2007 10789 10795